Substituted aryl or heteroaryl bicyclic inhibitor as well as preparation method and application thereof

By developing new compounds to target KRAS G12D mutations, the problem that existing drugs cannot effectively treat KRAS-related cancers is solved, and effective inhibition of KRAS G12D mutations and improved pharmacodynamic performance is achieved.

CN119060066APending Publication Date: 2024-12-03SUZHOU ZELGEN BIOPHARML +1
View PDF 0 Cites 18 Cited by

Patent Information

Application Number
CN202310643392.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-01
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing drugs have not yet been effective in targeting multiple KRAS G12D mutations, leading to the challenge of treating KRAS-related cancers, especially in diseases such as lung, pancreatic and colorectal cancer, with a lack of effective targeted treatment options.

Method used

A new type of compounds has been developed, which have an inhibitory effect on KRAS G12D mutation and its preparation method. The compounds with specific structures are formed through intramolecular cyclic reactions and metal catalysts catalyzed reactions to improve pharmacodynamic performance.

Benefits of technology

The compound showed significant inhibitory effects of KRAS G12D mutations, with better pharmacokinetic performance and lower toxic side effects, providing a potential treatment for KRAS-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060066A_ABST
    Figure CN119060066A_ABST
Patent Text Reader

Abstract

The invention relates to a substituted aryl or heteroaryl bicyclic inhibitor as well as a preparation method and application thereof. Specifically, the compound has a structure as shown in a formula (I), the invention further discloses a preparation method of the compound and application of the compound as a KRAS G12D mutation inhibitor, and the compound has a very good inhibition effect on KRAS G12D mutation and has better pharmacodynamic and pharmacokinetic performance and lower toxic and side effects. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicine, and specifically relates to a substituted aryl or heteroaryl bicyclic inhibitor and a preparation method and application thereof. Background Art

[0002] About a quarter of all human tumors are caused by RAS mutations, and nearly one million people lose their lives each year. In the RAS family, KRAS mutations account for 85% of all RAS mutations. KRAS mutations are found in nearly 90% of pancreatic cancers, 30-40% of colon cancers, and 15-20% of lung cancers (mainly non-small cell lung cancer).

[0003] KRAS protein is a small GTPase encoded by the KRAS gene and is an important regulatory protein for cell growth. Once KRAS is activated, it can activate multiple signaling pathways and promote cell proliferation. The most common sites for gene mutations in KRAS protein are codons 12, 13, and 61, among which mutations in codon 12 are the most common. The most important mutations in KRAS G12 mutations are G12A, G12C, G12D, G12V, G12S, etc., among which G12C, G12D, G12V, etc. mutations mainly occur in NSCLC, CRC, and pancreatic cancer. So far, there are still no drugs approved for marketing that target multiple KRAS mutations at the same time.

[0004] Since the KRAS G12D mutant target protein is pathologically associated with a variety of diseases, especially lung cancer, pancreatic cancer, colorectal cancer, etc., new KRAS G12D mutant inhibitors are currently needed for clinical treatment. Highly active KRAS G12D mutant inhibitors can more effectively treat diseases such as cancer caused by KRAS G12D mutations, and have the potential to reduce off-target effects, so they have more urgent clinical needs. Summary of the invention

[0005] The object of the present invention is to provide a novel class of compounds having an inhibitory effect on KRAS G12D mutation and / or better pharmacodynamic properties and uses thereof.

[0006] In a first aspect, the present invention provides a compound of formula (I), its stereoisomers, tautomers, crystalline forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs:

[0007]

[0008] In the formula,

[0009] Ring A is selected from the following substituted or unsubstituted groups: C6-C 14Aryl, 5-14 membered heteroaryl; wherein the substitution refers to substitution by one or more R;

[0010] Ring B is selected from the following group: substituted or unsubstituted: C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group; wherein the substitution refers to substitution by one or more R;

[0011] R 1 Selected from the following substituted or unsubstituted groups: H, deuterium, halogen, cyano, ester, amine, amide, sulfone, urea, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C1-C6 alkyloxy, C3-C6 cycloalkyloxy, 4-6 membered heterocyclyloxy; wherein the substitution refers to substitution by one or more R;

[0012] R 2 Selected from the following substituted or unsubstituted groups: C6-C 14 Aryl, 5-14 membered heteroaryl; wherein the substitution refers to substitution by one or more R;

[0013] R 3 Each is independently selected from the following substituted or unsubstituted groups: H, deuterium, halogen, cyano, ester, amine, amide, sulfone, urea, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C1-C6 alkyloxy, C3-C6 cycloalkyloxy, 4-6 membered heterocyclyloxy; wherein the substitution refers to substitution by one or more R;

[0014] m is an integer of 0, 1, 2, 3, 4, 5 or 6;

[0015] X 1 Selected from: a bond, O, NH, N(C1-C3 alkyl), CO or SO2;

[0016] X 2 Select from: N or CR 6 ; R 6 Selected from the group consisting of substituted or unsubstituted hydrogen, deuterium, C1-C 10 Alkyl, C1-C 10 Alkoxy, C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group, C1-C 10 Alkoxy C1-C6 alkylene, C3-C 20 Cycloalkyl C1-C6 alkylene, 4-20 membered saturated or unsaturated heterocyclic C1-C6 alkylene; wherein the substitution refers to substitution by one or more R;

[0017] X3 Selected from: a bond, O, NH or N(C1-C3 alkyl);

[0018] L is selected from a bond, or a substituted or unsubstituted group: C1-C 10 Alkylene, -CO-C1-C 10 Alkylene, C1-C6 alkylene-O-C1-C6 alkylene, C1-C6 alkylene-NH-C1-C6 alkylene, C1-C6 alkylene-N (C1-C3 alkyl) -C1-C6 alkylene, C1-C6 alkylene-CO-NH-C1-C6 alkylene, C1-C6 alkylene-CO-N (C1-C3 alkyl) -C1-C6 alkylene, C1-C6 alkylene-SO2-NH-C1-C6 alkylene, C1-C6 alkylene-SO2-N (C1-C3 alkyl) -C1-C6 alkylene, C3-C6 cycloalkylene, 4-6 membered heterocyclylene, -C1-C6 alkylene C3-C6 cycloalkylene-, -C1-C6 alkylene 4-6 membered heterocyclylene-; wherein, the substitution refers to substitution by one or more R; wherein the above substituents can be substituted with X at any end 2 connected;

[0019] Each R is the same or different and is independently selected from the group consisting of: H, deuterium, C2-C6 alkenyl, C2-C6 alkynyl, fluoroalkenyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, (C3-C6 cycloalkyl)C1-C6 alkyl, (4-6 membered heterocyclyl)C1-C6 alkyl, (C1-C6 alkoxy)C1-C6 alkyl, (C3-C6 cycloalkyloxy)C1-C6 alkyl, (4-6 membered heterocyclyloxy)C1-C6 alkyl, (C1-C6 alkyl)vinyl , deuterated (C1-C6 alkyl) vinyl, halogenated (C1-C6 alkyl) vinyl, (C1-C6 alkyl) ethynyl, deuterated (C1-C6 alkyl) ethynyl, halogenated (C1-C6 alkyl) ethynyl, (C3-C6 cycloalkyl) ethynyl, (4-6 membered heterocyclyl) ethynyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 halogenated alkoxy, C3-C6 cycloalkyl O-, 4-6 membered heterocyclyl O-, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C6-C 10 Aryl, 5-10 membered heteroaryl, halogen, nitro, hydroxyl, oxo (=O), cyano, ester, amine, amide, sulfone, urea, sulfonamide, C3-C6 cycloalkyl OH, 4-6 membered heterocyclyl OH.

[0020] In another preferred embodiment, ring B is a 6-10 membered saturated or unsaturated monocyclic or bicyclic heterocyclic group, preferably, ring B is an 8-membered or 9-membered bridged or spirocyclic heterocyclic group, more preferably, ring B is an 8-membered bridged heterocyclic group.

[0021] In another preferred embodiment, the compound has a structure represented by formula (IIA), (IIB), (IIC), (IID), (IIE) or (IIF):

[0022]

[0023] In the formula,

[0024] Ring A, R 1 , R 2 , R 3 , X 1 , X 2 , X 3 , L and m are defined as above.

[0025] In another preferred embodiment, the compound has a structure represented by formula (IIA) or (IIF).

[0026] In another preferred embodiment, the compound has a structure shown in formula (IIA).

[0027] In another preferred embodiment, the compound has a structure shown in formula (III):

[0028]

[0029] In the formula,

[0030] Ring A, R 1 , R 2 , R 3 , X 1 , X 3 , L and m are defined as above.

[0031] In another preferred embodiment, the compound has a structure shown in formula (IV):

[0032]

[0033] In the formula,

[0034] Ring A, R 1 , R 2 , R 3 , X 1 , L and m are defined as above.

[0035] In another preferred embodiment, the compound has a structure shown in formula (V):

[0036]

[0037] Among them, ring A, R 1 , R 2 , R 3 , L and m are defined as above.

[0038] In another preferred embodiment, ring A is selected from: phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl.

[0039] In another preferred embodiment, for

[0040] In another preferred embodiment, the compound has a structure shown in formula (VI):

[0041]

[0042] In the formula,

[0043] X 4 and X 5 Each independently selected from: N or CR 4 ;

[0044] Each R 4 Independently selected from the following substituted or unsubstituted groups: H, deuterium, halogen, cyano, ester, amine, amide, sulfone, urea, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C1-C6 alkyloxy, C3-C6 cycloalkyloxy, 4-6 membered heterocyclyloxy; wherein the substitution refers to substitution by one or more R;

[0045] R 1 , R 2 , R 3 , R and L are defined as above.

[0046] In another preferred embodiment, R 2 is selected from the following substituted or unsubstituted groups: phenyl, naphthyl, 5-6 membered monocyclic heteroaryl (such as pyridyl), 9-10 membered bicyclic heteroaryl (such as indazolyl, benzothiazolyl, benzothienyl, benzofuranyl, benzopyrazolyl), wherein the substitution is substituted by one or more groups selected from the following groups: halogen, hydroxyl, cyano, NH2, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C2-C6 alkenyl, C2-C6 alkynyl, ester, amine, amide, sulfone, urea, sulfonamide, C3-C6 cycloalkyl O-, 4-6 membered heterocyclyl O-, C3-C6 cycloalkyl OH, 4-6 membered heterocyclyl OH; preferably, R 2 Selected from:

[0047]

[0048]

[0049] In another preferred embodiment, X 1 For CO.

[0050] In another preferred embodiment, X 2 is N.

[0051] In another preferred embodiment, X 3 It is O or N(CH3).

[0052] In another preferred embodiment, L is CH2, CH(CH3). In another preferred embodiment, X 4 For CF.

[0053] In another preferred embodiment, X 5 For CCl.

[0054] In another preferred embodiment, the compound is selected from the following group:

[0055]

[0056]

[0057]

[0058]

[0059] In a second aspect, the present invention provides a method for preparing a compound of formula (I), a stereoisomer, a tautomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate, a solvate or a prodrug thereof, characterized in that it comprises the steps of:

[0060]

[0061] (i) in the presence of a base and a condensing agent, the compound of formula X-1 undergoes an intramolecular ring-closing reaction to obtain a compound of formula X-2;

[0062] (ii) in an inert solvent, in the presence of a base, in the presence of Pd or other metal catalysts, a compound of formula X-2 and a compound of formula R 2 -LG4 compound to obtain a compound of formula I;

[0063] LG1, LG2, LG3, and LG4 are leaving groups, each independently selected from: H, OH, halogen, OTf, OTs, OMs, -B(OH)2, -B(KBF3), -Sn( n Bu)3. wait;

[0064] The Pd catalyst is selected from: Pd(OAc)2, Pd(dba)2, Pd2(dba)3, XPhos PdG2, RuPhos PdG2, XantPhos-Pd-G2, cataCXium A-Pd-G2, XPhos PdG3, RuPhos PdG3, PdG3, SPhos PdG3, tBuXPhos-Pd-G3, XantPhos-Pd-G4, BrettPhos PG4, SPhos PdG4, cataCXium A-Pd-G4, Rockphos PdG4, etc.;

[0065] R 1 , R 2 , R 3 , Ring A, Ring B, X 1 , X 2 , X 3 , L and m are defined as above.

[0066] The third aspect of the present invention provides a pharmaceutical composition comprising one or more compounds described in the first aspect, their stereoisomers, tautomers, crystalline forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs; and a pharmaceutically acceptable carrier.

[0067] In another preferred embodiment, the pharmaceutical composition further comprises a drug selected from the following group: PD-1 inhibitors (such as nivolumab, pembrolizumab, pidilizumab, cemiplimab, JS-001, SHR-120, BGB-A317, IBI-308, GLS-010, GB-226, STW204, HX008, HLX10, BAT 1306, AK105, LZM009 or biosimilars of the above drugs, etc.), PD-L1 inhibitors (such as durvalumab, atezolizumab, avelumab, CS1001, KN035, HLX20, SHR-1316, BGB-A333, JS003, CS1003, KL-A167, F 520, GR1405, MSB2311 or biosimilars of the above drugs, etc.), CD20 antibodies (such as rituximab, obinutuzumab, ofatumumab, veltuzumab, tositumomab, 131I-tositumomab, ibritumomab, 90Y-ibritumomab, 90In-ibritumomab, ibritumomabtiuxetan, etc.), CD47 antibodies (such as Hu5F9-G4, CC-90002, TTI-621, TTI-622, OSE-172, SRF-231, ALX-148, NI-1701, SHR-1603, IBI188, IMM01), ALK inhibitors (such as Ceritinib, Alectinib, Brigatinib, Lorlatinib, Oclatinib), PI3K inhibitors (such as Idelalisib, D uvelisib, Dactolisib, Taselisib, Bimiralisib, Omipalisib, Buparlisib, etc.), BTK inhibitors (such as Ibrutinib, Tirabrutinib, Acalabrutinib, Zanubrutinib, Vecabrutinib, etc.), EGFR inhibitors (such as Afatinib, Gefitinib, Erlotinib, Lapatinib, Dacomitinib, Icotinib, Canertinib, Sapitinib, Naquotinib, Pyrotinib, Rocieletinib, Osimertinib, etc.), VEGFR inhibitors (such as Sorafenib, Pazopanib, Regorafenib, Sitravatinib, Ningetinib, Cabozantinib,Sunitinib, Donafenib, etc.), HDAC inhibitors (such as Givinostat, Tucidinostat, Vorinostat, Fimepinostat, Droxinostat, Entinostat, Dacinostat, Quisinostat, Tacedinaline, etc.), CDK inhibitors (such as Palbociclib, Ribociclib, Abemaciclib, Milciclib, Trilaciclib, Lerociclib, etc.), MEK inhibitors (such as Selumetinib (AZD6244), Trametinib (GSK1120212), PD0325901, U0126, Pimasertib (AS-703026), PD184352 (CI-1040), etc.), mTOR inhibitors (such as Visusertib, etc.), SHP2 inhibitors (such as RMC-4630, JAB-3068, TNO155, etc.), SOS1 inhibitors (such as BI1701963) or their combinations.

[0068] In a fourth aspect, the present invention provides a use of the compound as described in the first aspect, its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs, or the pharmaceutical composition as described in the third aspect, for preparing a drug for preventing and / or treating a disease associated with the activity or expression of the KRAS G12D mutation, preferably, the disease is a tumor or a disorder.

[0069] In another preferred embodiment, the disease is selected from the following group: lung cancer, breast cancer, prostate cancer, esophageal cancer, colorectal cancer, bone cancer, kidney cancer, gastric cancer, liver cancer, colon cancer, melanoma, lymphoma, blood cancer, brain tumor, myeloma, soft tissue sarcoma, pancreatic cancer, skin cancer.

[0070] In a fifth aspect, the present invention provides a non-diagnostic, non-therapeutic method for inhibiting KRAS G12D mutation, comprising the steps of administering to a subject in need thereof an effective amount of the compound as described in the first aspect, its stereoisomers, tautomers, crystalline forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs, or administering the pharmaceutical composition as described in the third aspect.

[0071] In another preferred embodiment, the subject is a mammal, preferably a human.

[0072] In a sixth aspect, the present invention provides an in vitro method for inhibiting the activity of the KRAS G12D mutant, comprising the steps of contacting the compound as described in the first aspect, its stereoisomers, tautomers, crystalline forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs, or the pharmaceutical composition as described in the third aspect with proteins or cells, thereby inhibiting the activity of the KRAS G12D mutant.

[0073] In another preferred embodiment, the cells are selected from the group consisting of macrophages, intestinal cells (including intestinal stem cells, intestinal epithelial cells), or a combination thereof.

[0074] In another preferred embodiment, the cells are from rodents (such as mice and rats) or primates (such as humans).

[0075] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. DETAILED DESCRIPTION

[0076] After long-term and in-depth research, the inventor unexpectedly prepared a new type of compound with inhibitory effect on KRAS G12D mutation and / or better pharmacodynamic performance. On this basis, the inventor completed the present invention.

[0077] the term

[0078] In the present invention, unless otherwise specified, the terms used have the general meanings well known to those skilled in the art.

[0079] The term "alkyl" refers to a straight or branched alkane group containing 1-20 carbon atoms, such as 1-18 carbon atoms, especially 1-18 carbon atoms, preferably 1-10 carbon atoms (C1-C10), and more preferably 1-6 carbon atoms (C1-C6). Typical "alkyl" includes methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, isobutyl, Pentyl, isopentyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, etc. In the present invention, alkyl also includes substituted alkyl. "Substituted alkyl" means that one or more positions in the alkyl are substituted, especially 1-4 substituents, which can be substituted at any position. Typical substitutions include, but are not limited to, one or more of the following groups: such as hydrogen, deuterium, halogen (for example, a monohalogen substituent or a polyhalogen substituent, the latter such as trifluoromethyl or an alkyl containing Cl3), cyano, nitro, oxygen (such as =O), trifluoromethyl, trifluoromethoxy, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aromatic ring, OR a , SR a、S(=O)R e 、S(=O)2R e 、P(=O)2R e 、S(=O)2OR e 、P(=O)2OR e NR b R c NR b S(=O)2R e NR b P(=O)2R e 、S(=O)2NR b R c 、P(=O)2NR b R c 、C(=O)OR d 、C(=O)R a 、C(=O)NR b R c 、OC(=O)R a 、OC(=O)NR b R c NR b C(=O)OR e NR d C(=O)NR b R c NR d S(=O)2NR b R c NR d P(=O)2NR b R c NR b C(=O)R a , or NR b P(=O)2R e , where R a may independently represent hydrogen, deuterium, C1-C6 alkyl, C3-C8 cycloalkyl, C2-C6 alkenyl, C3-C6 cycloalkenyl, C2-C6 alkynyl, 4-14 membered heterocyclyl, 5-14 membered heteroaryl or C6-C14 aryl, R b , R c and R d can independently represent hydrogen, deuterium, C1-C6 alkyl, C3-C8 cycloalkyl, 4-14 membered heterocyclyl, 5-14 membered heteroaryl or C6-C14 aryl, or R b and R c Together with the N atom, it can form a heterocyclic ring; R eIt can independently represent hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C2-C6 alkenyl, C3-C6 cycloalkenyl, C2-C6 alkynyl, 4-14 membered heterocyclyl, 5-14 membered heteroaryl or C6-C14 aryl. The above typical substituents, such as alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclyl, heteroaryl or aryl, can be optionally substituted.

[0080] The term "alkylene" refers to a group formed by removing a hydrogen atom from an alkyl or substituted alkyl group, such as methylene (eg or -CH2-), ethylene (such as ), propylene (such as ), isopropylidene (such as ), butylene (such as ), pentylene (such as ), hexamethylene (such as ), heptylene (such as ), In addition, the term also includes a methylene group of an alkylene group (such as C1-C18 alkylene group) replaced by a cycloalkylene group (such as C3-C20 cycloalkylene group), for example, "C1-C18 alkylene group C3-C20 cycloalkylene group" or "C3-C20 cycloalkylene group C1-C18 alkylene group". In the present invention, alkylene group also includes substituted alkylene group, and the substituent group can be halogenated (such as -CHF- or -CF2-), hydroxyl, cyano, nitro, etc.

[0081] The term "C1-C18 alkylene C3-C20 cycloalkylene" or "C3-C20 cycloalkylene C1-C18 alkylene" has the same meaning, and refers to a group formed by removing two hydrogen atoms from a cycloalkylalkyl or alkylcycloalkyl group, preferably C1-C6 alkylene C3-C6 cycloalkylene, such as In the present invention, "C1-C18 alkylene C3-C20 cycloalkylene" or "C3-C20 cycloalkylene C1-C18 alkylene" also includes substituted "C1-C18 alkylene C3-C20 cycloalkylene" or "C3-C20 cycloalkylene C1-C18 alkylene", and the substituent may be halogen, hydroxyl, cyano, nitro, etc.

[0082] In the present invention, the term "alkenyl" means a straight or branched hydrocarbon group containing one or more double bonds and generally having a length of 2 to 20 carbon atoms. Alkenyl is preferably C2-C6 alkenyl, more preferably C2-C4 alkenyl. Alkenyl includes, but is not limited to, for example, vinyl, propenyl, butenyl, 1-methyl-2-butene-1-yl, etc. In the present invention, alkenyl includes substituted alkenyl. In the present invention, alkenyl also includes substituted alkenyl, and the substituent can be halo, hydroxyl, cyano, nitro, etc.

[0083] The term "alkynyl" refers to a straight or branched hydrocarbon group containing one or more triple bonds and generally having a length of 2 to 20 carbon atoms. Alkynyl is preferably C2-C6 alkynyl, more preferably C2-C4 alkynyl. Alkynyl includes, but is not limited to, ethynyl, propynyl or similar groups. In the present invention, alkynyl also includes substituted alkynyl, and the substituent may be halo, hydroxyl, cyano, nitro, etc.

[0084] In the present invention, the term "cycloalkyl" refers to a fully saturated cyclic hydrocarbon compound group, including 1-4 rings, each ring containing 3-8 carbon atoms. 20 " refers to a cycloalkyl group containing 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms. The cycloalkyl group is preferably C3-C 14 Cycloalkyl, more preferably C3-C 10 Cycloalkyl, more preferably C3-C6 monocyclic cycloalkyl, C7-C 10 Bicyclic or tricyclic cycloalkyl. "Substituted cycloalkyl" means that one or more positions in the cycloalkyl are substituted, especially 1-4 substituents, which can be substituted at any position. In the present invention, "cycloalkyl" includes substituted cycloalkyl, and typical substitutions include but are not limited to one or more of the following groups: such as hydrogen, deuterium, halogen (for example, a monohalogen substituent or a polyhalogen substituent, the latter such as trifluoromethyl or an alkyl containing Cl3), nitrile, nitro, oxygen (such as =O), trifluoromethyl, trifluoromethoxy, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclic, aromatic, OR a , SR a 、S(=O)R e 、S(=O)2R e 、P(=O)2R e 、S(=O)2OR e 、P(=O)2OR e NR b R c NR b S(=O)2R e NR b P(=O)2R e 、S(=O)2NR b R c 、P(=O)2NR b R c 、C(=O)OR d 、C(=O)R a 、C(=O)NR b R c 、OC(=O)R a 、OC(=O)NR b R c NRb C(=O)OR e NR d C(=O)NR b R c NR d S(=O)2NR b R c NR d P(=O)2NR b R c NR b C(=O)R a , or NR b P(=O)2R e , where R a R may independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclyl, aryl or heteroaryl. b , R c and R d can independently represent hydrogen, deuterium, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, or R b and R c Together with the N atom, it can form a heterocyclic ring; R e Hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclic radical, aryl or heteroaryl can be independently represented. The above typical substituents can be optionally substituted. Typical substitutions also include spirocyclic, pyrimidocyclic or condensed ring substituents, especially spirocyclic alkyl, spirocyclic alkenyl, spirocyclic heterocyclic radical (excluding heteroaryl), pyrimidocyclic alkyl, pyrimidocyclic alkenyl, pyrimidocyclic heterocyclic radical (excluding heteroaryl), condensed cycloalkyl, condensed cycloalkenyl, condensed ring heterocyclic radical or condensed ring aromatic ring radical, and the above cycloalkyl, cycloalkenyl, heterocyclic radical and heteroaryl can be optionally substituted. The example of cycloalkyl includes but is not limited to: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl etc.

[0085] The term "C3-C20 cycloalkylene" refers to a group formed by removing two hydrogen atoms from a cycloalkyl group, such as: wait.

[0086] In the present invention, the term "heterocyclyl" refers to a fully saturated or partially unsaturated cyclic group (including but not limited to 3-7 membered monocyclic, 4-7 membered monocyclic, 6-11 membered bicyclic or 8-16 membered tricyclic or polycyclic system), wherein at least one heteroatom is present in the ring having at least one carbon atom. The term "4-20 membered heterocyclyl" refers to a heterocyclyl containing 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 ring atoms. "Heterocyclyl" has the same meaning as "saturated or unsaturated heterocyclyl". "Heterocyclyl" is preferably a 4-14 membered heterocyclyl (including but not limited to a 4-6 membered monocyclic, 7-10 membered bicyclic or 8-14 membered tricyclic or polycyclic system), more preferably a 4-12 membered heterocyclyl, more preferably a 4-10 membered heterocyclyl, such as a 4-6 membered monocyclic heterocyclyl, a 7-11 membered bicyclic or tricyclic heterocyclyl, more preferably a 4-8 membered heterocyclyl, more preferably a 4-6 membered heterocyclyl. Each heterocyclic ring containing heteroatoms may have 1, 2, 3 or 4 heteroatoms, each of which is independently selected from a nitrogen atom, an oxygen atom or a sulfur atom, wherein the nitrogen atom or the sulfur atom may be oxidized, and the nitrogen atom may also be quaternized. The heterocyclic group may be attached to the residue of any heteroatom or carbon atom of the ring or ring system molecule, preferably to an N or C atom on the ring or ring system molecule. Typical monocyclic heterocycles include, but are not limited to, azetidinyl, pyrrolidinyl, oxetanyl, pyrazolinyl, imidazolinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, hexahydroazepinyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxanyl and tetrahydro-1,1-dioxythiophene, and the like. The polycyclic heterocyclic group includes spirocyclic, condensed and bridged heterocyclic groups; wherein the spirocyclic, condensed and bridged heterocyclic groups involved are optionally connected to other groups through single bonds, or further connected to other cycloalkyl, heterocyclic, aryl and heteroaryl groups through any two or more atoms on the ring; the heterocyclic group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, alkylthio, alkylamino, halogen, amino, nitro, hydroxyl, thiol, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkylthio, oxo, carboxyl and carboxylate.

[0087] The term "4-20 membered heterocyclylene" refers to a group formed by removing two hydrogen atoms from a heterocyclyl group, such as: wait.

[0088] The term "C1-C18 alkylene 4-20 membered heterocyclylene" or "4-20 membered heterocyclylene C1-C18 alkylene" has the same meaning, and refers to a group formed by removing two hydrogen atoms from a cycloalkylalkyl or alkylcycloalkyl group, preferably a C1-C6 alkylene 4-6 membered heterocyclylene, such as, In the present invention, "C1-C18 alkylene 4-20 membered heterocyclylene" or "4-20 membered heterocyclylene C1-C18 alkylene" also includes substituted "C1-C18 alkylene 4-20 membered heterocyclylene" or "4-20 membered heterocyclylene C1-C18 alkylene", and the substituent may be halo, hydroxyl, cyano, nitro, etc.

[0089] In the present invention, the term "aryl" refers to an aromatic cyclic hydrocarbon group having 1 to 5 rings, especially a monocyclic and bicyclic group. 14 "Aryl" refers to an aromatic cyclic hydrocarbon compound radical containing 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring carbon atoms. Aryl is preferably C6-C 10 Aryl. Aryl includes phenyl, biphenyl or naphthyl. Where there are two or more aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group can be connected by a single bond (such as biphenyl) or fused (such as naphthalene, anthracene, etc.). "Substituted aryl" means that one or more positions in the aryl group are substituted, especially 1-3 substituents, which can be substituted at any position. Typical substitutions include, but are not limited to, one or more of the following groups: such as hydrogen, deuterium, halogen (for example, a monohalogen substituent or a polyhalogen substituent, the latter such as trifluoromethyl or an alkyl containing Cl3), cyano, nitro, oxo (such as =O), trifluoromethyl, trifluoromethoxy, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclyl, aryl, heteroaryl, OR a , SR a 、S(=O)R e 、S(=O)2R e 、P(=O)2R e 、S(=O)2OR e 、P(=O)2OR e NR b R c NR b S(=O)2R e NR b P(=O)2R e 、S(=O)2NR b R c 、P(=O)2NR b R c 、C(=O)OR d 、C(=O)R a 、C(=O)NR b R c、OC(=O)R a 、OC(=O)NR b R c NR b C(=O)OR e NR d C(=O)NR b R c NR d S(=O)2NR b R c NR d P(=O)2NR b R c NR b C(=O)R a , or NR b P(=O)2R e , where R a may independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclic or aryl, R b , R c and R d can independently represent hydrogen, deuterium, alkyl, cycloalkyl, heterocyclic or aromatic ring, or R b and R c Together with the N atom, it can form a heterocyclic ring; R e It can independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclic radical or aryl. The above typical substituents can be optionally substituted. Typical substitutions also include condensed ring substituents, especially condensed ring alkyl, condensed ring alkenyl, condensed ring heterocyclic radical or condensed ring aromatic ring radical, and the above cycloalkyl, cycloalkenyl, heterocyclic radical and heterocyclic aryl can be optionally substituted.

[0090] The term "heteroaryl" refers to an aromatic cyclic hydrocarbon group containing 1 to 4 heteroatoms, wherein the heteroatoms are selected from oxygen, nitrogen and sulfur. Among them, "5-14 membered heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms. The heteroaryl is preferably 5 to 10 rings, more preferably 5 or 6, such as pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazoxinyl, triazolyl and tetrazolyl. "Heteroaryl" may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, alkylthio, alkylamino, halogen, amino, nitro, hydroxy, mercapto, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylthio, oxo, carboxyl and carboxylate.

[0091] In the present invention, the term "alkoxy" refers to a straight chain or branched alkoxy group, including alkyl-O-, alkyl-O-alkyl, wherein "C1-C 18 "Alkoxy" refers to a straight or branched chain alkoxy group having 1 to 18 carbon atoms, including C1-C 18 Alkyl-O-, -C1-C6 alkyl-O-C1-C6 alkyl, including but not limited to methoxy, ethoxy, propoxy, isopropoxy and butoxy, etc. Preferably it is C1-C8 alkoxy, more preferably C1-C6 alkoxy.

[0092] In the present invention, the term "cycloalkyloxy" refers to cycloalkyl-O-, wherein "C3-C 20 "Cycloalkyloxy" refers to C3-C 20 Cycloalkyl-O-, wherein C3-C 20 Cycloalkyl is as defined above.

[0093] In the present invention, the term "heterocyclyloxy" refers to heterocyclyl-O-, wherein "4-20 membered heterocyclyloxy" refers to 4-20 membered heterocyclyl-O-, wherein the 4-20 membered heterocyclyl is as defined above.

[0094] In the present invention, the term "C1-C 18 "Alkyleneoxy" refers to "C1-C 18 Alkoxy is a group obtained by removing a hydrogen atom.

[0095] In the present invention, the term "halogen" or "halo" refers to chlorine, bromine, fluorine, and iodine.

[0096] In the present invention, the term "halogenated" means substituted with halogen.

[0097] In the present invention, the term "deuterated" means substituted with deuterium.

[0098] In the present invention, the term "hydroxyl" refers to a group having the structure OH.

[0099] In the present invention, the term "nitro" refers to a group having the structure NO2.

[0100] In the present invention, the term "cyano group" refers to a group having the structure CN.

[0101] In the present invention, the term "ester group" refers to a group with the structure -COOR, wherein R represents hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heterocycle or substituted heterocycle. The ester group is preferably -COO C1-C6 alkyl.

[0102] The term "amine group" refers to a group with the structure -NRR', wherein R and R' can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heterocyclyl or substituted heterocyclyl, heteroaryl or substituted heteroaryl, as defined above. R and R' can be the same or different in the dialkylamine fragment. The amine group is preferably NH2, NHC1-C6 alkyl, N(C1-C6 alkyl)2, C3-C6 cycloalkyl NH-, 4-6 membered heterocyclyl NH-.

[0103] The term "amido" refers to a group with the structure -CONRR', wherein R and R' can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heterocycle or substituted heterocycle, as defined above. R and R' can be the same or different in the dialkylamine fragment. The amide group is preferably CONH2, NHCO(C1-C6 alkyl), NHCO(C3-C6 cycloalkyl).

[0104] The term "sulfone group" refers to a group with the structure -SO2R, wherein R can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclic or substituted heterocyclic, as defined above. The sulfone group is preferably -SO2C1-C6 alkyl.

[0105] The term "sulfonamide" refers to a group with the structure -SO2NRR', wherein R can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclyl or substituted heterocyclyl, as defined above. Sulfonamide is preferably -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2NH(C3-C6 cycloalkyl).

[0106] The term "urea group" refers to a group having the structure -NRCONR'R", wherein R, R' and R" can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclyl or substituted heterocyclyl, as defined above. R, R' and R" can be the same or different in the dialkylamine fragment. Urea groups are preferably -NHCONH2, -NHCONH(C1-C6 alkyl).

[0107] The term "alkylaminoalkyl" refers to a group with the structure -RNHR', wherein R and R' can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclyl or substituted heterocyclyl, as defined above. R and R' can be the same or different. Alkylaminoalkyl is preferably -C1-C6 alkyleneNHC1-C6 alkyl.

[0108] The term "dialkylaminoalkyl" refers to a group with the structure -RNHR'R", wherein R, R' and R" can independently represent alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclyl or substituted heterocyclyl, as defined above. R, R' and R" can be the same or different in the dialkylamino fragment. The dialkylaminoalkyl is preferably -C1-C6 alkylene N(C1-C6 alkyl)2.

[0109] The term "heterocyclylalkyl" refers to a group with the structure -RR', wherein R can independently represent alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl; and R' represents a heterocycle or a substituted heterocycle.

[0110] In the present invention, the term "substituted" refers to one or more hydrogen atoms on a specific group being replaced by a specific substituent. The specific substituent is the substituent described above, or the substituent appearing in each embodiment. Unless otherwise specified, a substituted group may have a substituent selected from a specific group at any substitutable position of the group, and the substituent may be the same or different at each position. It should be understood by those skilled in the art that the combination of substituents contemplated by the present invention is those stable or chemically feasible combinations. The substituents include, for example (but not limited to): halogen, hydroxyl, cyano, carboxyl (-COOH), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 12-membered heterocyclic group, aryl, heteroaryl, C1-C8 aldehyde group, C2-C10 acyl group, C2-C10 ester group, amine group, C1-C6 alkoxy group, C1-C10 sulfonyl group, and C1-C6 urea group, etc.

[0111] Unless otherwise stated, any heteroatom with unsatisfied valence is assumed to have sufficient hydrogen atoms to complete its valence.

[0112] When a substituent is a non-terminal substituent, it is a substituent of the corresponding group, for example, alkyl for alkylene, cycloalkyl for cycloalkylene, heterocyclyl for heterocyclylene, alkoxy for alkyleneoxy, and the like.

[0113] In the present invention, a plurality refers to 2, 3, 4, or 5.

[0114] Active ingredients

[0115] As used herein, "compounds of the present invention" refers to compounds represented by Formula I, and also includes stereoisomers or optical isomers, pharmaceutically acceptable salts, prodrugs or solvates of the compounds of Formula I.

[0116] The salts that may be formed by the compounds of the present invention also belong to the scope of the present invention. Unless otherwise specified, the compounds of the present invention are understood to include their salts. The term "salt" used herein refers to an acidic or basic salt formed with an inorganic or organic acid and a base. In addition, when the compound of the present invention contains a basic fragment, it includes but is not limited to pyridine or imidazole, and contains an acidic fragment, including but not limited to carboxylic acid, the zwitterions ("inner salts") that may be formed are included in the scope of the term "salt". Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful, for example, in separation or purification steps in the preparation process. The compounds of the present invention may form salts, for example, Compound I reacts with a certain amount of acid or base, such as an equivalent amount, and is salted out in a medium, or freeze-dried in an aqueous solution.

[0117] The compounds of the present invention contain basic fragments, including but not limited to amines or pyridine or imidazole rings, which may form salts with organic or inorganic acids. Typical acids that can form salts include acetates (such as acetic acid or trihaloacetic acid, such as trifluoroacetic acid), adipates, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphor salt, camphorsulfonate, cyclopentanepropionate, diglycolate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide

[0013] The invention also includes but is not limited to the following: esters, isothioates (e.g., 2-hydroxyethanesulfonate), lactates, maleates, methanesulfonates, naphthalenesulfonates (e.g., 2-naphthalenesulfonate), nicotinates, nitrates, oxalates, pectinates, persulfates, phenylpropionates (e.g., 3-phenylpropionate), phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (e.g., formed with sulfuric acid), sulfonates, tartrates, thiocyanates, toluenesulfonates such as p-toluenesulfonates, dodecanoates, and the like.

[0118] Some compounds of the present invention may contain acidic fragments, including but not limited to carboxylic acids, which may form salts with various organic or inorganic bases. Typical base-formed salts include ammonium salts, alkali metal salts such as sodium, lithium, potassium salts, alkaline earth metal salts such as calcium, magnesium salts, and salts formed with organic bases (such as organic amines), such as benzathine, dicyclohexylamine, hepamine (salt formed with N,N-di(dehydroabietyl)ethylenediamine), N-methyl-D-glucamine, N-methyl-D-glucamide, tert-butylamine, and salts formed with amino acids such as arginine, lysine, etc. Basic nitrogen-containing groups can be combined with halide quaternary ammonium salts, such as small molecule alkyl halides (such as chlorides, bromides and iodides of methyl, ethyl, propyl and butyl), dialkyl sulfates (such as dimethyl sulfate, diethyl sulfate, dibutyl sulfate and dipentyl sulfate), long chain halides (such as chlorides, bromides and iodides of decyl, dodecyl, tetradecyl and tetradecyl), aralkyl halides (such as benzyl and phenyl bromides), etc.

[0119] Prodrugs and solvates of the compounds of the present invention are also within the scope of the invention. The term "prodrug" herein refers to a compound that undergoes chemical transformation by metabolic or chemical processes to produce a compound, salt, or solvate of the present invention when treating a related disease. The compounds of the present invention include solvates, such as hydrates.

[0120] The compounds, salts or solvates of the present invention may exist in tautomeric forms (such as amides and imino ethers). All these tautomers are part of the present invention.

[0121] All stereoisomers of the compounds (e.g., those due to asymmetric carbon atoms that may exist for various substitutions), including enantiomeric and diastereomeric forms, are contemplated by the present invention. Individual stereoisomers of the compounds of the present invention may not exist simultaneously with other isomers (e.g., as a pure or substantially pure optical isomer having a particular activity), or may be mixtures, such as racemates, or mixtures with all other stereoisomers or portions thereof. The chiral centers of the present invention have two configurations, S or R, as defined by the 1974 recommendations of the International Union of Pure and Applied Chemistry (IUPAC). Racemic forms can be resolved by physical methods, such as fractional crystallization, or by crystallization of diastereoisomers derived therefrom, or by separation by chiral column chromatography. Individual optical isomers can be obtained from racemates by suitable methods, including but not limited to conventional methods, such as recrystallization after salt formation with an optically active acid.

[0122] The compounds of the present invention are prepared, separated and purified to obtain compounds with a weight content of equal to or greater than 90%, for example, equal to or greater than 95%, equal to or greater than 99% ("very pure" compounds), which are listed in the text description. Such "very pure" compounds of the present invention are also considered part of the present invention.

[0123] All configurational isomers of the compounds of the present invention are within the scope of the invention, whether in mixture, pure or very pure form. The definition of the compounds of the present invention includes both cis (Z) and trans (E) olefin isomers, as well as cis and trans isomers of carbocyclic and heterocyclic rings.

[0124] Throughout the specification, groups and substituents may be selected to provide stable fragments and compounds.

[0125] Specific functional groups and chemical term definitions are detailed below. For purposes of this invention, chemical elements are referred to as Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th Ed. Definitions of specific functional groups are also described therein. In addition, the basic principles of organic chemistry as well as specific functional groups and reactivity are also described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, which is incorporated by reference in its entirety.

[0126] Certain compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention encompasses all compounds, including their cis and trans isomers, R and S enantiomers, diastereomers, (D) isomers, (L) isomers, racemic mixtures and other mixtures. In addition, asymmetric carbon atoms may represent substituents, such as alkyl. All isomers and their mixtures are included in the present invention.

[0127] According to the present invention, the ratio of isomers contained in the mixture of isomers can be various. For example, in the mixture of only two isomers, there can be the following combinations: 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0, and all ratios of isomers are within the scope of the present invention. Similar ratios that are easily understood by ordinary technicians in this profession, and ratios for more complex mixtures of isomers are also within the scope of the present invention.

[0128] The present invention also includes isotopically labeled compounds that are equivalent to the original compounds disclosed herein. However, in practice, it is common for one or more atoms to be replaced by atoms having a different atomic mass or mass number than the original atoms. Examples of isotopes of the compounds of the present invention include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine isotopes, such as 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 The compounds of the present invention, or enantiomers, diastereomers, isomers, or pharmaceutically acceptable salts or solvates, wherein the isotopes or other isotopic atoms of the above compounds are all within the scope of the present invention. Certain isotope-labeled compounds of the present invention, such as 3 H and 14 Radioisotopes of C are also included and are useful in tissue distribution experiments of drugs and substrates. 3 H and carbon-14, i.e. 14 C, their preparation and detection are relatively easy. It is the first choice among isotopes. In addition, heavier isotope substitutions such as deuterium, i.e. 2 H, due to its good metabolic stability in certain therapies has advantages, such as increasing half-life or reducing dosage in vivo, therefore, in some cases, it can be preferred. Isotope-labeled compounds can be prepared by general methods by replacing readily available isotope-labeled reagents with non-isotopic reagents using the schemes disclosed in the examples.

[0129] If a synthesis of a specific enantiomer of the compound of the present invention is to be designed, it can be prepared by asymmetric synthesis, or derivatized with a chiral auxiliary, the resulting diastereomeric mixture can be separated, and the chiral auxiliary can be removed to obtain the pure enantiomer. In addition, if the molecule contains a basic functional group, such as an amino acid, or an acidic functional group, such as a carboxyl group, a diastereomeric salt can be formed with a suitable optically active acid or base, and then separated by conventional means such as fractional crystallization or chromatography, and then the pure enantiomer can be obtained.

[0130] As described herein, the compounds of the present invention can be replaced with any number of substituents or functional groups to expand its scope. Generally, the term "substituted" appears before or after the term "optional", and the general formula including substituents in the formulation of the present invention refers to the use of a specified structural substituent to replace the hydrogen free radical. When multiple positions in a specific structure are substituted by multiple specific substituents, the substituents can be the same or different at each position. The term "substituted" used herein includes all allowed organic compound substitutions. In a broad sense, allowed substituents include non-cyclic, cyclic, branched non-branched, carbocyclic and heterocyclic, aromatic and non-aromatic organic compounds. In the present invention, heteroatom nitrogen can have hydrogen substituents or any allowed organic compounds described above to supplement its valence. In addition, the present invention is not intended to limit the allowed substitution of organic compounds in any way. The present invention believes that the combination of substituents and variable groups is very good in the treatment of diseases in the form of stable compounds, such as infectious diseases or proliferative diseases. As used herein, the term "stable" refers to compounds that are stable and that maintain the structural integrity of the compound over a period of time sufficient to be detected, and preferably over a period of time sufficient to be effective, as used herein for the purposes described above.

[0131] The metabolites of the compounds and pharmaceutically acceptable salts thereof involved in the present application, as well as prodrugs that can be converted into the structures of the compounds and pharmaceutically acceptable salts involved in the present application and in vivo, are also included in the claims of the present application.

[0132] Preparation method

[0133] The preparation method of the compound of formula (I) of the present invention is described in more detail below, but these specific methods do not constitute any restriction to the present invention. The compounds of the present invention can also be conveniently prepared by combining various synthetic methods described in this specification or known in the art, and such combination can be easily carried out by those skilled in the art to which the present invention belongs.

[0134] Typically, the preparation process of the compound of the present invention is as follows, wherein the raw materials and reagents used can be purchased through commercial channels unless otherwise specified.

[0135] Preferably, the compounds of the present invention are prepared by the following method:

[0136]

[0137] (i) in the presence of a base and a condensing agent, the compound of formula X-1 undergoes an intramolecular ring-closing reaction to obtain a compound of formula X-2;

[0138] (ii) in an inert solvent, in the presence of a base, in the presence of Pd or other metal catalysts, a compound of formula X-2 and a compound of formula R 2 -LG4 compound to obtain a compound of formula I;

[0139] LG1, LG2, LG3, and LG4 are leaving groups, each independently selected from: H, OH, halogen, OTf, OTs, OMs, -B(OH)2, -B(KBF3), -Sn( n Bu)3. wait;

[0140] The Pd catalyst is selected from: Pd(OAc)2, Pd(dba)2, Pd2(dba)3, XPhos PdG2, RuPhos PdG2, XantPhos-Pd-G2, cataCXium A-Pd-G2, XPhos PdG3, RuPhos PdG3, PdG3, SPhos PdG3, tBuXPhos-Pd-G3, XantPhos-Pd-G4, BrettPhos PG4, SPhos PdG4, cataCXium A-Pd-G4, Rockphos PdG4, etc.;

[0141] R 1 , R 2 , R 3 , Ring A, Ring B, X 1 , X 2 , X 3 , L and m are defined as above.

[0142] Pharmaceutical compositions and methods of administration

[0143] The pharmaceutical composition of the present invention is used to prevent and / or treat the following diseases: inflammation, cancer, cardiovascular disease, infection, immune disease, and metabolic disease.

[0144] The compounds of general formula (I) can be used in combination with other drugs known to treat or improve similar conditions. When administered in combination, the administration method and dosage of the original drug can remain unchanged, and the compound of formula I can be taken simultaneously or subsequently. When the compound of formula I is taken simultaneously with one or more other drugs, a pharmaceutical composition containing one or more known drugs and the compound of formula I can be preferably used. Drug combination also includes taking the compound of formula I and one or more other known drugs in overlapping time periods. When the compound of formula I is used in combination with one or more other drugs, the dosage of the compound of formula I or the known drug may be lower than the dosage of them taken alone.

[0145] The drugs or active ingredients that can be used in combination with the compounds of general formula (I) include but are not limited to: PD-1 inhibitors (such as nivolumab, pembrolizumab, pidilizumab, cemiplimab, JS-001, SHR-120, BGB-A317, IBI-308, GLS-010, GB-226, STW204, HX008, HLX10, BAT 1306, AK105, LZM 009 or biosimilars of the above drugs, etc.), PD-L1 inhibitors (such as durvalumab, atezolizumab, avelumab, CS1001, KN035, HLX20, SHR-1316, BGB-A333, JS003, CS1003, KL-A167, F 520, GR1405, MSB2311 or biosimilars of the above drugs, etc.), CD20 antibodies (such as rituximab, obinutuzumab, ofatumumab, veltuzumab, tositumomab, 131I-tositumomab, ibritumomab, 90Y-ibritumomab, 90In-ibritumomab, ibritumomabtiuxetan, etc.), CD47 antibodies (such as Hu5F9-G4, CC-90002, TTI-621, TTI-622, OSE-172, SRF-231, ALX-148, NI-1701, SHR-1603, IBI188, IMM01), ALK inhibitors (such as Ceritinib, Alectinib, Brigatinib, Lorlatinib, Ocatinib), PI3K inhibitors (such as Idelalisib, Duvelisib, Dactolisib, Taselisib, Bimiralisib, Omip alisib, Buparlisib, etc.), BTK inhibitors (such as Ibrutinib, Tirabrutinib, Acalabrutinib, Zanubrutinib, Vecabrutinib, etc.), EGFR inhibitors (such as Afatinib, Gefitinib, Erlotinib, Lapatinib, Dacomitinib, Icotinib, Canertinib, Sapitinib, Naquotinib, Pyrotinib, Rociletinib, Osimertinib, etc.), VEGFR inhibitors (such as Sorafenib, Pazopanib, Regorafenib, Sitravatinib, Ningetinib, Cabozantinib, Sunitinib, Donafenib, etc.), HDAC inhibitors (such as Givinostat, Tucidinostat, Vorinostat, Fimepinostat, Droxinostat, Entinostat, Dacinostat, Quisinostat, Tacedinaline, etc.), CDK inhibitors (such as Palbociclib , Ribociclib, Abemaciclib, Milciclib, Trilaciclib, Lerociclib, etc.), MEK inhibitors (such as Selumetinib (AZD6244), Trametinib (GSK1120212), PD0325901, U0126, Pimasertib (AS-703026), PD184352 (CI-1040), etc.), mTOR inhibitors (such as Visusertib, etc.), SHP2 inhibitors (such as RMC-4630, JAB-3068, TNO155, etc.) or a combination thereof. The dosage form of the pharmaceutical composition of the present invention includes (but is not limited to): injection, tablet, capsule, aerosol, suppository, film, pill, external ointment, controlled release or sustained release or nano preparation.

[0146] The pharmaceutical composition of the present invention comprises a safe and effective amount of the compound of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Usually, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, and more preferably, contains 10-1000 mg of the compound of the present invention per dose. Preferably, the "one dose" is a capsule or tablet.

[0147] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0148] There is no particular limitation on the administration of the compound or pharmaceutical composition of the present invention. Representative administrations include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.

[0149] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0150] Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.

[0151] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.

[0152] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0153] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances, and the like.

[0154] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0155] Dosage forms for topical administration of the compounds of the invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.

[0156] The treatment method of the present invention can be used alone or in combination with other treatment methods or therapeutic drugs.

[0157] When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage during administration is a pharmaceutically effective dosage, and for a person weighing 60 kg, the daily dosage is usually 1 to 2000 mg, preferably 50 to 1000 mg. Of course, the specific dosage should also take into account factors such as the route of administration and the health status of the patient, which are all within the skill of a skilled physician.

[0158] The present invention also provides a method for preparing a pharmaceutical composition, comprising the steps of: mixing a pharmaceutically acceptable carrier with the compound of the general formula (IA) and formula (IB) of the present invention or their crystal forms, pharmaceutically acceptable salts, hydrates or solvates, thereby forming a pharmaceutical composition.

[0159] The present invention also provides a treatment method, which comprises the steps of administering to a subject in need of treatment the compound of general formula (I) of the present invention, or a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, or administering the pharmaceutical composition of the present invention, for inhibiting KRAS G12D mutation.

[0160] Compared with the prior art, the present invention has the following main advantages:

[0161] (1) The compound has a good inhibitory effect on KRAS G12D mutation;

[0162] (2) The compound has better pharmacodynamics, pharmacokinetic properties and lower toxic side effects.

[0163] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are generally performed under conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0164] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.

[0165] The structure of the compound of the present invention is confirmed by nuclear magnetic resonance (NMR) and liquid chromatography-mass spectrometry (LC-MS).

[0166] NMR was detected using a Bruker AVANCE-400 nuclear magnetic spectrometer. The measurement solvents included deuterated dimethyl sulfoxide (DMSO-d6), deuterated acetone (CD3COCD3), deuterated chloroform (CDCl3) and deuterated methanol (CD3OD), etc. Tetramethylsilane (TMS) was used as the internal standard, and the chemical shift was measured in parts per million (ppm).

[0167] Liquid chromatography-mass spectrometry (LC-MS) was detected using a Waters SQD2 mass spectrometer, and HPLC was determined using an Agilent 1100 high pressure chromatograph (Microsorb 5micron C18 100 x 3.0 mm column).

[0168] The thin layer chromatography silica gel plate uses Qingdao GF254 silica gel plate, TLC uses 0.15-0.20 mm, and preparative thin layer chromatography uses 0.4 mm-0.5 mm. Column chromatography generally uses Qingdao silica gel 200-300 mesh silica gel as a carrier.

[0169] The starting materials in the examples of the present invention are all known and commercially available, or can be synthesized using or according to literature data reported in the art.

[0170] Unless otherwise specified, all reactions of the present invention are carried out under the protection of dry inert gas (such as nitrogen or argon) with continuous magnetic stirring, and the reaction temperatures are all degrees Celsius.

[0171] Example

[0172] Example A1 Preparation of (6aS,7S,10R)-3-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-4-chloro-2-fluoro-6a,7,8,9,10,11-hexahydro-6H,13H-7,10-epi-imidoazepine[2,1-c]benzo[f][1,4]oxazepine-13-one

[0173]

[0174] Step 1: Preparation of tert-butyl (1R,2S,5S)-2-((3-bromo-2-chloro-4-fluoro-6-(methoxycarbonyl)phenoxy)methyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0175] Under nitrogen protection, NaH (40 mg, 60% wt, 1 mmol, 1 eq) was added to a solution of (1R, 2S, 5S)-2-(hydroxymethyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (0.24 g, 1 mmol) in anhydrous THF (4 mL) at 0°C. The reaction solution was reacted at 0°C for 0.5 hr, and then methyl 4-bromo-3-chloro-2,5-difluorobenzoate (0.28 g, 1 mmol, 1 eq) was added. The obtained reaction solution was reacted at room temperature for 2 hr, and then a saturated aqueous ammonium chloride solution was added under ice bath, and then extracted with ethyl acetate. The combined organic phase was concentrated under reduced pressure to obtain the target product. It was directly used in the next reaction without further purification.

[0176] LC-MS: m / z 507 (M+H) + .

[0177] Step 2: Preparation of 4-bromo-2-(((1R,2S,5S)-8-(tert-butyloxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-2-yl)methoxy)-3-chloro-5-fluorobenzoic acid

[0178] Under ice bath, the (1R,2S,5S)-2-((3-bromo-2-chloro-4-fluoro-6-(methoxycarbonyl)phenoxy)methyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester obtained in the previous step was added to a mixed solvent of THF (5mL) and MeOH (0.6mL), followed by addition of LiOH aqueous solution (0.3mL, 6.25M) and water (0.5mL). The obtained reaction solution was reacted at room temperature for 3 hours, then adjusted to pH 6 with citric acid under ice bath, and then added with saturated ammonium chloride aqueous solution, followed by extraction with ethyl acetate. The combined organic phase was concentrated under reduced pressure to obtain the target product. It was directly used in the next reaction without further purification.

[0179] LC-MS: m / z 493 (M+H) + .

[0180] Step 3: Preparation of tert-butyl (6aS,7S,10R)-3-bromo-4-chloro-2-fluoro-13-oxo-6a,7,8,9,10,11-hexahydro-6H,13H-7,10-epi-imido[2,1-c]benzo[f][1,4]-14-carboxylate

[0181] To a DCM (5 mL) solution of 4-bromo-2-(((1R,2S,5S)-8-(tert-butyloxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-2-yl)methoxy)-3-chloro-5-fluorobenzoic acid obtained in the previous step was added TEA (0.28 mL) under ice bath, followed by dropwise addition of 1-propylphosphoric anhydride (1.1 mL, 50 wt% / EtOAc). The resulting reaction solution was reacted for 10 min, and then DCM and saturated aqueous ammonium chloride solution were added to separate the layers. The aqueous phase was separated and extracted with ethyl acetate. The combined organic phases were concentrated under reduced pressure. The residue was separated by preparative liquid phase separation to obtain the target product (45.1 mg, 9.5% yield).

[0182] LC-MS: m / z 475 (M+H) + .

[0183] Step 4: Preparation of tert-butyl (6aS,7S,10R)-3-(2-((tert-butyloxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)-4-chloro-2-fluoro-13-oxo-6a,7,8,9,10,11-hexahydro-6H,13H-7,10-epi-imidoazepine[2,1-c]benzo[f][1,4]oxazepine-14-carboxylate

[0184] Under nitrogen protection, a mixture of tert-butyl (7-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiazol-2-yl)carboxylate (70 mg), tert-butyl (6aS,7S,10R)-3-bromo-4-chloro-2-fluoro-13-oxo-6a,7,8,9,10,11-hexahydro-6H,13H-7,10-epiimidoazepine[2,1-c]benzo[f][1,4]oxazepine-14-carboxylate (40 mg, 0.084 mmol), cataCXium A Pd G2 (4 mg) and K3PO4 (40 mg) in H2O (0.12 mL) and THF (0.6 mL) was reacted at 70°C for 4 hr and then concentrated under reduced pressure. The residue was separated by preparative liquid phase to give the target product (17 mg, 30.6% yield).

[0185] LC-MS: m / z 663 (M+H) + .

[0186] Step 5: Preparation of (6aS,7S,10R)-3-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-4-chloro-2-fluoro-6a,7,8,9,10,11-hexahydro-6H,13H-7,10-epi-imidoazepine[2,1-c]benzo[f][1,4]oxazepine-13-one

[0187] A solution of tert-butyl (4-(4-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-9-chloro-7-fluoro-5-oxo-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-8-yl)-7-fluorobenzo[d]thiazol-2-yl)carboxylate (17 mg, 0.0257 mmol) in trifluoroacetic acid (0.5 mL) was stirred at room temperature for 16 h and then concentrated under reduced pressure. The residue was separated by preparative liquid phase to give the desired product (5 mg, 42% yield).

[0188] LC-MS: m / z 463 (M+H) + .

[0189] The following examples were synthesized using different starting materials according to the method of Example A1:

[0190] Example A2 2-amino-4-((6aS,7S,10R)-4-chloro-2-fluoro-13-oxo-6a,7,8,9,10,11-hexahydro-6H,13H-7,10-epi-imidoazepine[2,1-c]benzo[f][1,4]oxazepine-3-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0191]

[0192] LC-MS: m / z 487 (M+H) + .

[0193] Example A3 (6aS, 7S, 10R) -4-chloro-3- (8-ethynyl-7-fluoro-3-hydroxynaphthyl-1-yl) -2-fluoro-6a, 7, 8, 9, 10, 11-hexahydro-6H, 13H-7, 10- epiiminoazepine [2, 1-c] benzo [f] [1, 4] oxazepine-13-one

[0194]

[0195] LC-MS: m / z 481 (M+H) + .

[0196] Example A4 (6aS, 7S, 10R) -4-chloro-3-(8-ethyl-7-fluoro-3-hydroxynaphthyl-1-yl) -2-fluoro-6a, 7, 8, 9, 10, 11-hexahydro-6H, 13H-7, 10- epi-imidoazepine [2, 1-c] benzo [f] [1, 4] oxazepine-13-one

[0197]

[0198] LC-MS: m / z 485 (M+H) + .

[0199] Example Pharmaceutical Composition

[0200] Oral tablet:

[0201] Example A1 or A2 is added with auxiliary fillers microcrystalline cellulose (101) and lactose monohydrate, an internal disintegrant croscarmellose sodium, a binder hydroxypropyl methylcellulose (E15), an external disintegrant croscarmellose sodium, and a lubricant magnesium stearate to prepare a 10 mg oral tablet.

[0202] Injection:

[0203] In Example A1 or A2, sodium sulfobutyl beta-cyclodextrin, sodium chloride, water for injection, etc. are added to prepare an injection preparation.

[0204] Biological test cases

[0205] Biological test evaluation

[0206] The following biological test examples further describe and explain the present invention, but these examples are not intended to limit the scope of the present invention.

[0207] 1. Cell Proliferation Assay

[0208]

[0209] Positive reference: MRTX1133

[0210]

[0211] Experimental procedures

[0212] Use a nanoliter pipetting system to add the diluted test compound to a 384-well cell culture plate and set up duplicate wells. Add an equal volume of culture medium to the positive control group; add an equal volume of DMSO to the negative control group, and centrifuge at 1000 rpm for 1 min at room temperature.

[0213] The cells were inoculated into a) 384 culture plate, and the negative control group was added with an equal volume of cells, and the positive control group was added with an equal volume of culture medium only. Centrifuged at 1000 rpm for 1 min at room temperature, and the final DMSO concentration of the compound was 0.5%, and incubated in a 37°C, 5% CO2 constant temperature incubator for 7 days.

[0214] Add 20 μL / well 3D to b) in a 384-well cell culture plate, shake at 320 rpm for 20 min in the dark, and incubate at room temperature for 2 hrs in the dark.

[0215] The luminescence value was read using Envision multi-function microplate reader.

[0216] 3. Data Analysis

[0217] The inhibition rate (IR) of the test compound was calculated using the following formula: IR (%) = (1 – (RLU 化合物 –RLU 空白对照 ) / (RLU 溶媒对照 –RLU 空白对照 ))*100%. The inhibition rates of compounds at different concentrations were calculated in Excel, and then the inhibition curves were plotted and related parameters were calculated using GraphPad Prism software, including the minimum inhibition rate, maximum inhibition rate, and IC 50 .

[0218] The results showed that the compounds of the present invention showed good inhibitory activity against KRAS G12D mutation.

[0219] Pharmacokinetic testing evaluation

[0220] Male SD rats weighing about 220 g were fasted overnight and orally administered with a 30 mg / kg solution of the compound of the present invention or the reference compound. Blood was collected at 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 12.0 and 24 h after administration of the compound of the present invention, and the concentration of the compound of the present invention or the reference compound in plasma was determined by LC / MS / MS.

[0221] It can be seen from the test results that the compound of the present invention has good pharmacokinetic properties.

[0222] Pharmacodynamics test evaluation of antitumor activity (AsPC-1CDX tumor model)

[0223] 100uL containing 5x10 6 AsPC-1 tumor cell suspension was subcutaneously inoculated into the right posterior abdomen of nude mice. The health of the mice was monitored daily, and the measurement was started when the tumor grew to a palpable size. The tumor volume was calculated using the formula: 0.5xLxW 2 , where L and W represent the length and width of the tumor, respectively. The tumor grows to 200 mm 3 The mice were randomly divided into groups. The corresponding dose of compound was given by gavage every day, and their general condition was monitored. Tumors were measured 3 times a week, and body weight was measured twice a week.

[0224] It can be seen from the test results that the compound of the present invention has a good anti-tumor effect.

[0225] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A compound of formula (I), its stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug: In the formula, Ring A is selected from the following substituted or unsubstituted groups: C6-C 14 Aryl, 5-14 membered heteroaryl; wherein, The substitution refers to substitution by one or more R; Ring B is selected from the following group: substituted or unsubstituted: C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group; wherein the substitution refers to substitution by one or more R; R 1 Selected from the following substituted or unsubstituted groups: H, deuterium, halogen, cyano, ester, amine, amide, sulfone, urea, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C1-C6 alkyloxy, C3-C6 cycloalkyloxy, 4-6 membered heterocyclyloxy; wherein the substitution refers to substitution by one or more R; R 2 Selected from the following substituted or unsubstituted groups: C6-C 14 Aryl, 5-14 membered heteroaryl; wherein the substitution refers to substitution by one or more R; R 3 Each is independently selected from the following substituted or unsubstituted groups: H, deuterium, halogen, cyano, ester, amine, amide, sulfone, urea, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C1-C6 alkyloxy, C3-C6 cycloalkyloxy, 4-6 membered heterocyclyloxy; wherein the substitution refers to substitution by one or more R; m is an integer of 0, 1, 2, 3, 4, 5 or 6; X 1 Selected from: a bond, O, NH, N(C1-C3 alkyl), CO or SO2; X 2 Select from: N or CR 6 ; R 6 Selected from the group consisting of substituted or unsubstituted hydrogen, deuterium, C1-C 10 Alkyl, C1-C 10 Alkoxy, C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group, C1-C 10 Alkoxy C1-C6 alkylene, C3-C 20 Cycloalkyl C1-C6 alkylene, 4-20 membered saturated or unsaturated heterocyclic C1-C6 alkylene; wherein the substitution refers to substitution by one or more R; X 3 Selected from: a bond, O, NH or N(C1-C3 alkyl); L is selected from a bond, or a substituted or unsubstituted group: C1-C 10 Alkylene, -CO-C1-C 10 Alkylene, C1-C6 alkylene-O-C1-C6 alkylene, C1-C6 alkylene-NH-C1-C6 alkylene, C1-C6 alkylene-N (C1-C3 alkyl) -C1-C6 alkylene, C1-C6 alkylene-CO-NH-C1-C6 alkylene, C1-C6 alkylene-CO-N (C1-C3 alkyl) -C1-C6 alkylene, C1-C6 alkylene-SO2-NH-C1-C6 alkylene, C1-C6 alkylene-SO2-N (C1-C3 alkyl) -C1-C6 alkylene, C3-C6 cycloalkylene, 4-6 membered heterocyclylene, -C1-C6 alkylene C3-C6 cycloalkylene-, -C1-C6 alkylene 4-6 membered heterocyclylene-; wherein, the substitution refers to substitution by one or more R; wherein the above substituents can be substituted with X at any end 2 connected; Each R is the same or different and is independently selected from the group consisting of: H, deuterium, C2-C6 alkenyl, C2-C6 alkynyl, fluoroalkenyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, (C3-C6 cycloalkyl)C1-C6 alkyl, (4-6 membered heterocyclyl)C1-C6 alkyl, (C1-C6 alkoxy)C1-C6 alkyl, (C3-C6 cycloalkyloxy)C1-C6 alkyl, (4-6 membered heterocyclyloxy)C1-C6 alkyl, (C1-C6 alkyl)vinyl , deuterated (C1-C6 alkyl) vinyl, halogenated (C1-C6 alkyl) vinyl, (C1-C6 alkyl) ethynyl, deuterated (C1-C6 alkyl) ethynyl, halogenated (C1-C6 alkyl) ethynyl, (C3-C6 cycloalkyl) ethynyl, (4-6 membered heterocyclyl) ethynyl, C1-C6 alkoxy, C1-C6 deuterated alkoxy, C1-C6 halogenated alkoxy, C3-C6 cycloalkyl O-, 4-6 membered heterocyclyl O-, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C6-C 10 Aryl, 5-10 membered heteroaryl, halogen, nitro, hydroxyl, oxo (=O), cyano, ester, amine, amide, sulfone, urea, sulfonamide, C3-C6 cycloalkyl OH, 4-6 membered heterocyclyl OH.

2. The compound according to claim 1, its stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug, characterized in that: It has a structure shown by formula (IIA), (IIB), (IIC), (IID), (IIE) or (IIF): In the formula, Ring A, R 1 , R 2 , R 3 , X 1 , X 2 , X 3 , L and m are as defined in claim 1.

3. The compound according to any one of claims 1 to 2, its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug, characterized in that: It has the structure shown in formula (III): In the formula, Ring A, R 1 , R 2 , R 3 , X 1 , X 3 , L and m are as defined in claim 1.

4. The compound, stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof according to any one of claims 1 to 3, characterized in that: It has the structure shown in formula (IV): In the formula, Ring A, R 1 , R 2 , R 3 , X 1 , L and m are as defined in claim 1.

5. The compound according to any one of claims 1 to 4, its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug, characterized in that: The compound has a structure shown in formula (V) Among them, ring A, R 1 , R 2 , R 3 , L and m are as defined in claim 1.

6. The compound, stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof according to any one of claims 1 to 5, characterized in that: The compound has a structure shown in formula (VI) In the formula, X 4 and X 5 Each independently selected from: N or CR 4 ; Each R 4 Independently selected from the following substituted or unsubstituted groups: H, deuterium, halogen, cyano, ester, amine, amide, sulfone, urea, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C1-C6 alkyloxy, C3-C6 cycloalkyloxy, 4-6 membered heterocyclyloxy; wherein the substitution refers to substitution by one or more R; R 1 , R 2 , R 3 , R and L are as defined in claim 1.

7. The compound, stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof according to any one of claims 1 to 6, characterized in that: R 2 is selected from the following substituted or unsubstituted groups: phenyl, naphthyl, 5-6 membered monocyclic heteroaryl (such as pyridyl), 9-10 membered bicyclic heteroaryl (such as indazolyl, benzothiazolyl, benzothienyl, benzofuranyl, benzopyrazolyl), wherein the substitution is substituted by one or more groups selected from the following groups: halogen, hydroxyl, cyano, NH2, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C2-C6 alkenyl, C2-C6 alkynyl, ester, amine, amide, sulfone, urea, sulfonamide, C3-C6 cycloalkyl O-, 4-6 membered heterocyclyl O-, C3-C6 cycloalkyl OH, 4-6 membered heterocyclyl OH; preferably, R 2 Selected from:

8. The compound, stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof according to any one of claims 1 to 7, characterized in that: The compound is selected from the group consisting of:

9. A pharmaceutical composition, characterized in that Comprising one or more compounds according to any one of claims 1 to 8, stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof; and a pharmaceutically acceptable carrier.

10. Use of the compound according to any one of claims 1 to 8, its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug, or the pharmaceutical composition according to claim 9, characterized in that: Used for preparing a drug for preventing and / or treating a disease associated with the activity or expression of KRAS G12D mutation, preferably, the disease is a tumor or a disorder.

Citation Information

Cited By

  • Linearly substituted oxazepin-5-one KRAS-g12d inhibitors

    WO2025194134A1

  • Ras inhibitors

    WO2025240847A1

  • Methods of treating a ras protein-related disease or disorder

    WO2025255438A1

  • Therapeutic compositions and methods for managing treatment-related effects

    WO2025265060A1

  • Ras inhibitors

    WO2026006747A1